| Literature DB >> 35076531 |
Suyanto Suyanto1, Shashi Kandel2, Rahmat Azhari Kemal1, Arfianti Arfianti1.
Abstract
This study assesses the status of health-related quality of life (HRQOL) among coronavirus survivors living in rural and urban districts in Riau province, Indonesia. The cross-sectional study was conducted among 468 and 285 Coronavirus disease (COVID-19) survivors living in rural and urban areas, respectively in August 2021. The St. George Respiratory Questionnaire (SGRQ) was used to measure the HRQOL of COVID-19 survivors. A higher total score domain corresponds to worse quality of life status. Quantile regression with the respect to 50th percentile found a significant association for the factors living in rural areas, being female, having comorbidities, and being hospitalized during treatment, with total score of 4.77, 2.43, 7.22, and 21.27 higher than in their contra parts, respectively. Moreover, having received full vaccination had the score 3.96 in total score. The HRQOL of COVID-19 survivors living in rural areas was significantly lower than in urban areas. Factors such as living in rural areas, female sex, having comorbidities, and history of symptomatic COVID-19 infection were identified as significant predictors for lower quality of life. Meanwhile, having full vaccination is a significant predictor for a better quality of life. The results of this study can provide the targeted recommendations for improvement of HRQOL of COVID-19 survivors.Entities:
Keywords: COVID-19; SGRQ score; quality of life
Year: 2022 PMID: 35076531 PMCID: PMC8788287 DOI: 10.3390/idr14010005
Source DB: PubMed Journal: Infect Dis Rep ISSN: 2036-7430
Figure 1Geographical Location of Riau Province, Indonesia.
Figure 2Frequency Distribution of SGRQ score domain between rural and urban region.
Characteristics of the study participants.
| Characteristics | Rural Region | Urban Region | |
|---|---|---|---|
| Age | 0.10 | ||
| Median (IQR)-year | 31 (25–41) | 29 (23–42) | |
| Age group | 0.60 | ||
| >51 years (>90% percentile) | 36 (9.4) | 50 (10.7) | |
| ≤51 years (≤90% percentile) | 349 (90.6) | 418 (89.3) | |
| Sex group | 0.18 | ||
| Female | 278 (59.4) | 247 (64.2) | |
| Male | 190 (40.6) | 138 (35.8) | |
| Education level group | 0.28 | ||
| Average education | 165 (42.9) | 219 (46.8) | |
| Higher education | 220 (57.1) | 249 (53.2) | |
| Income group | <0.01 | ||
| Non-permanent income | 169 (36.1) | 174 (45.2) | |
| Permanent income | 299 (63.9) | 211 (54.8) | |
| Having comorbidity | 0.28 | ||
| Yes | 43 (9.2) | 45 (11.7) | |
| No | 425 (90.8) | 340 (88.3) | |
| Vaccination status | <0.01 | ||
| Fully vaccinated | 293 (62.6) | 186 (48.3) | |
| Partially vaccinated | 46 (9.8) | 48 (12.5) | |
| Unvaccinated | 129(27.6) | 151 (39.2) | |
| Disease severity | <0.01 | ||
| Moderate/Severe | 57 (12.2) | 27 (7) | |
| Mild | 215 (45.9) | 250 (64.9) | |
| Asymptomatic | 196 (41.9) | 108 (28.1) |
The value indicated absolute number (percentage) unless otherwise stated. IQR (interquartile range).
Distribution of SGRQ domain scores for COVID-19 survivors in the study population.
| Characteristics | N | Symptoms | Activity | Impacts | Total |
|---|---|---|---|---|---|
| Overall | |||||
| Mean (SD) | 13.9 (15.7) | 18.1 (27.3) | 12.5 (17.7) | 14.5 (18.5) | |
| Median (IQR) | 9.7 (2.6–18.5) | 0 (0–29.6) | 4.6 (0–16.3) | 6.5 (1.5–21.6) | |
| Regions of residence | |||||
| Rural | 468 | 9.7 (2.6–18.2) | 0 (0–35.5) * | 9.0 (0–22.9) * | 8.4 (2.3–25.4) * |
| Urban | 385 | 9.7 (0–21.7) | 0 (0–18.5) | 3.8 (0–11.6) | 4.3 (0.7–14.0) |
| Age group | |||||
| >51 years | 86 | 12.3 (4.7–19.6) | 6.0 (0–43.2) | 7.8 (0–19.5) | 9.1 (2.2–27.0) |
| ≤51 years | 767 | 9.7 (0–18.3) | 0 (0–25.9) | 4.2 (0–16.2) | 6.2 (1.5–20.1) |
| Sex group | |||||
| Female | 525 | 9.7 (0–18.5) | 5.8(0–35.2) * | 7.6 (0–17.7) * | 7.9 (2.1–24.5) * |
| Male | 328 | 9.8 (2.6–18.3) | 0 (0–12.3) | 2.0 (0–15.8) | 4.0 (0.7–16.0) |
| Education level group | |||||
| Average education | 384 | 9.7 (2.6–18.3) | 0 (0–35.1) | 4.2 (0–19.4) | 6.4 (1.5–25) |
| Higher education | 469 | 10.5 (2.3–18.4) | 0 (25.2) | 4.6 (0–15/6) | 6.5 (1.9–19.8) |
| Income group | |||||
| Non-permanent income | 343 | 9.7 (2.6–19.6) | 6.0 (0–31.7) | 7.6 (0–21.7) | 7.8 (1.6–25) |
| Permanent income | 510 | 9.8 (2.3–18.3) | 0 (0–25.1) | 4.0 (0–15.6) | 5.8 (1.5–19.7) |
| Having comorbidity | |||||
| Yes | 88 | 18.3 (12.2–35.5) * | 33.2 (0–67.1) * | 11.6 (0–37.7) * | 22.2 (4.1–49.5) * |
| No | 765 | 9.7 (0–17.0) | 0 (0–24.1) | 4.1(0–15.6) | 5.9 (1.5–18.3) |
| Vaccination Status | |||||
| Fully Vaccinated | 479 | 9.7 (2.4–17.7) | 0 (0–24.6) * | 4.0 (0–15.2) * | 4.5 (0.8–17.7)* |
| Partially Vaccinated | 94 | 10.5 (0–19.6) | 0 (0–18.5) | 4.0 (0–11.7) | 5.5 (2.1–13.7) |
| Unvaccinated | 280 | 10.5 (2.6–21.3) | 11.2 (0–41.6) | 8.0 (0–27.5) | 9.6 (2.4–27.8) |
| Disease severity | |||||
| Moderate/Severe | 84 | 27.6 (15.5–38.1) * | 36.4 (0–68.3) * | 18.8 (9.6–48.6) * | 26.6 (12.5–52.4) * |
| Mild | 465 | 12.3 (4.7–22) | 5.8 (0–35.6) | 6 (0–21.6) | 8 (2.1–24.4) |
| Asymptomatic | 304 | 2.6 (0–12.3) | 0 (0–6) | 0 (0–8.1) | 2.3 (0.4–8.5) |
* Significant difference median of score between characteristics groups.
Coefficient of Quintile regression with 95% confidence interval to predict the median of SGRQ domain score from the predictor exposure.
| Predictors | Levels | Symptom | Activity | Impacts | Total Domain |
|---|---|---|---|---|---|
| Region of residence | Rural | 2.56 * | 2.98 | 3.99 * | 4.77 * |
| (2.56–2.56) | (0.25–1.46) | (3.43–5.87) | (3.06–5.54) | ||
| Urban | 0 | 0 | 0 | 0 | |
| Sex group | Female | 2.98 | 3.82 | 2.43 * | |
| (0.17–3.97) | (0.16–4.22) | (1.27–3.86) | |||
| Male | 0 | 0 | 0 | ||
| Having comorbidity | Yes | 8.74 * | 15.84 * | 4.40 | 7.22 * |
| (4.23–14.65) | (3.73–30.20) | (−0.07–9.83) | (3.12–17.57) | ||
| No | 0 | 0 | 0 | 0 | |
| Vaccination status | Fully vaccinated | −2.98 * | −3.99 * | −3.96 * | |
| (−8.68–1.61) | (−5.90–3.15) | (−5.87–2.88) | |||
| Partially vaccinated | −2.98 * | −3.84 * | −3.00 | ||
| (−7.86–2.83) | (−4.32–0.25) | (−5.15–0.61) | |||
| Unvaccinated | 0 | 0 | 0 | ||
| Disease severity | Moderate/Severe | 19.45 * | 32.62 * | 15.00 * | 21.27 * |
| (15.65–29.09) | (22.21–38.95) | (10.51–19.42) | (16.22–24.51) | ||
| Mild | 9.71 * | 2.09 | 3.97 * | 5.18 * | |
| (9.71–9.71) | (0.51–4.30) | (2.99–4.31) | (4.74–6.43) | ||
| Asymptomatic | 0 | 0 | 0 | 0 |
Values in brackets denote 95% confidence interval. The * indicates significant difference.